Abstract: The present invention relates to a novel preventive and/or therapeutic drug for myocardial infarction. The present invention provides a preventive and/or therapeutic drug for myocardial infarction or myocardial ischemia-reperfusion injury, the drug containing a lipid membrane structure retaining adenosine.

Abstract: An object of the present invention is to identify a novel single nucleotide polymorphism (SNP) associated with the onset and the advancement of inflammatory diseases such as myocardial infarction. The present invention provides a method for judging an inflammatory disease which comprises detecting at least 1 type of genetic polymorphism existing in at least one gene selected from the group consisting of the LBP-32 gene, the TSBP gene, and the WAP gene.

Abstract: An object of the present invention is to identify a novel single nucleotide polymorphism (SNP) associated with the onset and the advancement of inflammatory diseases such as myocardial infarction. The present invention provides a method for judging an inflammatory disease which comprises detecting at least 1 type of genetic polymorphism existing in at least one gene selected from the group consisting of the LBP-32 gene, the TSBP gene, and the WAP gene.

Abstract: It is an object of the present invention to provide a method for determining inflammatory diseases including myocardial infarction as a typical example, which involves identifying polymorphisms associated with myocardial infarction and using the gene polymorphisms, an oligonucleotide that can be used for the method, a kit for diagnosing inflammatory diseases, a therapeutic agent for inflammatory diseases, and the like. The present invention provides a method for determining an inflammatory disease, which comprises detecting at least one type of gene polymorphism existing in a proteasome subunit ? type 6 gene.

Abstract: A single nucleotide polymorphism occurring on a leptin receptor gene is analyzed and an inflammatory disease is examined on the basis of the analytical data. Further, a substance capable of changing the interaction between the leptin receptor and galectin-2 is selected to thereby screen a remedy for an inflammatory disease.

Abstract: A gene polymorphism on a Toll-like receptor gene is analyzed and an inflammatory disease is examined based on the results of the analysis. A remedy for an inflammatory disease is screened by selecting a substance capable of altering the interaction between Toll-like receptor and galectin-2.

Abstract: An object of the present invention is to identify a novel single nucleotide polymorphism (SNP) associated with the onset and the advancement of inflammatory diseases such as myocardial infarction. The present invention provides a method for judging an inflammatory disease which comprises detecting at least 1 type of genetic polymorphism existing in at least one gene selected from the group consisting of the LBP-32 gene, the TSBP gene, and the WAP gene.

Abstract: A single nucleotide polymorphism occurring on a leptin receptor gene is analyzed and an inflammatory disease is examined on the basis of the analytical data. Further, a substance capable of changing the interaction between the leptin receptor and galectin-2 is selected to thereby screen a remedy for an inflammatory disease.

Abstract: It is an object of the present invention to provide a method for determining inflammatory diseases including myocardial infarction as a typical example, which involves identifying polymorphisms associated with myocardial infarction and using the gene polymorphisms, an oligonucleotide that can be used for the method, a kit for diagnosing inflammatory diseases, a therapeutic agent for inflammatory diseases, and the like. The present invention provides a method for determining an inflammatory disease, which comprises detecting at least one type of gene polymorphism existing in a proteasome subunit ? type 6 gene.

Abstract: The object of the present invention is to determine inflammatory diseases such as myocardial infarction by identifying single nucleotide polymorphisms (SNPs) associated with myocardial infarction and utilizing these SNPs. The present invention provides a method for determining an inflammatory disease, which comprises detecting at least one gene polymorphism existing in at least one gene selected from the group consisting of a lymphotoxin-? (LT-?) gene, an I Kappa B-like (IKBL) gene, and a BAT1 gene; an oligonucleotide used in said method; a kit for diagnosing an inflammatory disease which comprises said oligonucleotide; and use thereof. The present invention further provides a method for treating an inflammatory disease; and a method for screening for a therapeutic agent for an inflammatory disease.

Abstract: The present invention relates to a novel preventive and/or therapeutic drug for myocardial infarction. The present invention provides a preventive and/or therapeutic drug for myocardial infarction or myocardial ischemia-reperfusion injury, the drug containing a lipid membrane structure retaining adenosine.

Abstract: A gene polymorphism on a Toll-like receptor gene is analyzed and an inflammatory disease is examined based on the results of the analysis. A remedy for an inflammatory disease is screened by selecting a substance capable of altering the interaction between Toll-like receptor and galectin-2.

Abstract: An object of the present invention is to identify a novel single nucleotide polymorphism (SNP) associated with the onset and development of inflammatory diseases such as myocardial infarction. The present invention provides a method for judging inflammatory diseases which comprises detecting at least one gene polymorphism in the galectin-2 gene.

Abstract: A method for diagnosis of heart failure in a human subject, which comprises the step of: measuring an endoplasmic reticulum (ER)-initiated apoptotic signal such as CHOP in a biological sample originated from the subject is disclosed. According to the invention, by employing the new marker in stead of or in addition to a conventional cardiac marker such as BNP, more accurate diagnosis of heart failure can be attained.

Abstract: The object of the present invention is to determine inflammatory diseases such as myocardial infarction by identifying single nucleotide polymorphisms (SNPs) associated with myocardial infarction and utilizing these SNPs. The present invention provides a method for determining an inflammatory disease, which comprises detecting at least one gene polymorphism existing in at least one gene selected from the group consisting of a lymphotoxin-? (LT-?) gene, an I Kappa B-like (IKBL) gene, and a BAT1 gene; an oligonucleotide used in said method; a kit for diagnosing an inflammatory disease which comprises said oligonucleotide; and use thereof. The present invention further provides a method for treating an inflammatory disease; and a method for screening for a therapeutic agent for an inflammatory disease.

Abstract: An agent for curing ischemic myocardial disease which contains an effective amount of diadenosine 5',5'"-p.sup.1,p.sup.4 -tetraphosphate (Ap4A) of formula (I): ##STR1## or a pharmaceutically-acceptable salt thereof.